A Randomized, Double-blind, Placebo-controlled, Multiple-administration, Multiple-dose, Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of D-0120 Tablets in Healthy Subjects and Hyperuricemia Patients in China
Latest Information Update: 18 May 2022
At a glance
- Drugs D-0120 (Primary)
- Indications Gout; Hyperuricaemia
- Focus Adverse reactions
- Sponsors InventisBio
Most Recent Events
- 05 May 2022 Status changed from recruiting to completed.
- 28 Sep 2020 Planned End Date changed from 31 Jul 2021 to 31 Dec 2021.
- 28 Sep 2020 Planned primary completion date changed from 31 Dec 2020 to 30 Jun 2021.